Tobin Schilke - 31 Dec 2024 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Dec 2024
Net transactions value
+$2,184
Form type
4
Filing time
03 Jan 2025, 16:34:15 UTC
Previous filing
02 Jul 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $2,184 +1,000 +0.52% $2.18 194,666 31 Dec 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).